Navigation Links
Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
Date:9/26/2007

COLORADO SPRINGS, Colo., Sept. 26 /PRNewswire-FirstCall/ -- Spectranetics Corporation (Nasdaq: SPNC) today announced it has enrolled the first patient in the PATENT trial utilizing the Company's TURBO elite(TM) laser catheters in combination with the recently FDA cleared TURBO-Booster(TM).

The PATENT trial is a prospective registry of 100 patients at up to 10 sites in Germany. The trial will assess patency as measured by duplex ultrasound at various intervals up to 12 months following the procedure. It will also assess safety as measured by adverse events up to 12 months following the procedure. In the initial procedure performed at the Leipzig Heart Center, four focal lesions were treated successfully with the TURBO-Booster and TURBO elite 2.0mm catheter in a 20cm long stented superficial femoral artery.

"The initial result from this Spectranetics device looks very promising, as the new features allow for ablation of more tissue in larger vessels," said Andrej Schmidt, M.D., of the University of Leipzig-Heart Center. "Instent restenosis in a superficial femoral artery represents one of the most challenging procedures in our practice. The current standard of care, such as repeat balloon angioplasty, does not have good results as these lesions tend to reoccur. We are very excited with the start of this study in Germany, and we look forward to examining the mid- and long-term results of this new therapy."

John G. Schulte, Spectranetics' President and Chief Executive Officer, commented, "We are very pleased to have begun this trial at one of Europe's most prestigious medical centers. We believe that instent restenosis in the superficial femoral artery may represent 25% to 35% of all above-the-knee proce
'/>"/>

SOURCE Spectranetics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... This report analyzes the worldwide markets for Enteral ... Enteral Feeding Pumps, Nasogastric Tubes, and Others. The ... Japan , Europe , ... and Rest of World. Annual estimates and forecasts are provided ... analysis is provided for these markets. The report ...
(Date:9/30/2014)... MiMedx Group, Inc. (NASDAQ: MDXG ... tissue and patent-protected processes to develop and market advanced ... Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, ... Scientific Officer, will present at the Stem Cell Meeting ... October 7, 2014, at 5:00PM Pacific Daylight Time. ...
(Date:9/30/2014)... -- STUDY OBJECTIVES The objective of BCC ... overview of the current and future characteristics of ... objective is to present a comprehensive analysis and ... tool in the treatment of various diseases. ... the protein therapeutics market, which includes peptide hormones, ...
Breaking Medicine Technology:Global Enteral Feeding Devices Industry 2Global Enteral Feeding Devices Industry 3Global Enteral Feeding Devices Industry 4Global Enteral Feeding Devices Industry 5Global Enteral Feeding Devices Industry 6Global Enteral Feeding Devices Industry 7Global Enteral Feeding Devices Industry 8Global Enteral Feeding Devices Industry 9Global Enteral Feeding Devices Industry 10Global Enteral Feeding Devices Industry 11Global Enteral Feeding Devices Industry 12Global Enteral Feeding Devices Industry 13Global Enteral Feeding Devices Industry 14Global Enteral Feeding Devices Industry 15Global Enteral Feeding Devices Industry 16Global Enteral Feeding Devices Industry 17Global Enteral Feeding Devices Industry 18Global Enteral Feeding Devices Industry 19MiMedx to Present at the Stem Cell Meeting on the Mesa 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4
... WOONSOCKET, R.I., Jan. 6, 2011 A new CVS ... a three-year period for patients with one or more ... medications as doctors direct may save the health care ... study findings revealed robust reductions in emergency department visits ...
... DIEGO, Jan. 6, 2011 Arena Pharmaceuticals, Inc. (Nasdaq: ... is scheduled to present at the 29th Annual J.P. Morgan ... Pacific Time (7:00 p.m. Eastern Time) at the Westin St. ... and Chief Executive Officer, is scheduled to provide a corporate ...
Cached Medicine Technology:CVS Caremark Study Finds Medication Adherence Leads to Lower Health Care Costs, Even After Accounting for Increased Prescription Drug Spending 2CVS Caremark Study Finds Medication Adherence Leads to Lower Health Care Costs, Even After Accounting for Increased Prescription Drug Spending 3Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference 2Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference 3
(Date:10/1/2014)... small protein beta-amyloid is strongly associated with Alzheimer,s disease; ... this peptide is the causal agent of the onset ... such confirmation is that beta-amyloid is not harmful when ... is when it self-assembles to form the so-called amyloid ... target, beta-amyloid alone, but with multiple ones because each ...
(Date:10/1/2014)... and Physical Sciences Research Council (EPSRC) will focus ... control systems which run, for example, manufacturing plants, ... network. , The research will help understand ... the systems behind our critical national infrastructure. ... Systems (RITICS), based at Imperial College London, is ...
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog post ... , Senior citizens can qualify for affordable term ... seniors who are over 50 years old. Some term ... medical examination. , Term life insurance with a simplified ... qualify. Having life insurance during retirement is important for ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new ... insurance prices for smokers. , Smoking will always have ... quotes is the best method to find affordable coverage. ... who need coverage. , Whole life insurance premiums ... policy. Since the coverage is permanent, the initial ...
(Date:10/1/2014)... 2014 Farmington Company today announced ... mission and visual identity helping brokers, consultants and ... them to create greater benefit communication synergies. They ... on empowering customers to better leverage Farmington Company’s ... jewel of the rebrand is the refreshed tagline: ...
Breaking Medicine News(10 mins):Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Farmington Company Launches Rebrand and New Positioning 2
... of a key protein mediator of inflammation reduced radiation ... help to patients receiving radiation therapy, according to researchers ... Reporting in Molecular Cancer Therapeutics , the researchers ... against radiation toxicity when given before exposure to treatment, ...
... Montreal, September 1, 2009 A recent study published ... reinforced the correlation between being overweight, smoking and breast ... subjects were not diagnosed for BRCA1 and BRCA2 gene ... Instead, women with such gene mutations were excluded to ...
... PORTLAND, Ore., Sept. 1 The Regence Foundation announced today ... Oregon , WithinReach , Critical Access Hospital Network ... all support nonprofit programs with innovative plans to improve quality of care ... Regence Foundation, our mission is to support health care transformation by partnering ...
... , , Springfield AARP Volunteers ... Senator, Congressmen to Tackle Issue , , ... taking a break from Washington, AARP is making sure they don,t ... care system. With a giant inflatable Rx bottle as a ...
... , , SAN FRANCISCO, Sept. 1 ... announced that it has received the Department of Health Care Services 2009 ... throughout the state of California for Medi-Cal managed care plans. , ... said Dr. Kelly Pfeifer, SFHP Medical Director. "It,s a testament to ...
... , , , , ... Center recently honored Vigilan with the Silver Award recognizing the Administrator ... The 2009 Product & Technology Awards Program is the ... products and services for older adults, their families and care providers. ...
Cached Medicine News:Health News:Inhibition of NF-kappa B, a key inflammatory protein, reduced radiation toxicity in zebrafish 2Health News:Breast cancer: Risk increases for smokers and overweight women 2Health News:Regence Foundation Awards Nearly $250,000 in Grants to Northwest Nonprofits 2Health News:Sen. Durbin, Congressmen Get Health Care Reform 'Message in a Bottle' from AARP 2Health News:San Francisco Health Plan Recognized as Top Health Plan for Quality in the California Medi-Cal Program 2Health News:San Francisco Health Plan Recognized as Top Health Plan for Quality in the California Medi-Cal Program 3Health News:Vigilan Earns Honor in the 2009 Product & Technology Awards Program by Mature Market Resource Center 2
... Made with elastic fabric, these head ... you need to begin testing. Each Electro-Cap ... to the International 10-20 System. When you ... you are using with your head cap ...
... When testing takes you into the OR, ER, ... protection of Cadwells new shielded electrodes. Keeping noise ... and paired disc electrode has a special shielded ... the damaging effects of 60-cycle interference. That means ...
... orbital implant was conceived by Arthur C. ... a comprehensive review of the literature on ... dating back to 1885 (Mules 1885). This ... the performance of contemporary implants, allowed Perry ...
... Viewing System was developed in New ... the surgical supervision of Professor Stanley Chang, ... New York Cornell Medical Center and later ... on the market and immediately revolutionized the ...
Medicine Products: